Anglo-Swedish pharmaceuticals giant AstraZeneca on Tuesday agreed to buy US biopharma firm Fusion for up to $2.4 billion, in the group’s latest expansion into cancer treatments.
Mon. Dec 23rd, 2024
Anglo-Swedish pharmaceuticals giant AstraZeneca on Tuesday agreed to buy US biopharma firm Fusion for up to $2.4 billion, in the group’s latest expansion into cancer treatments.